$1.13
3.67% yesterday
Nasdaq, Dec 24, 10:49 pm CET
ISIN
US47010C3007
Symbol
JAGX

Jaguar Health, Inc. Stock price

$1.13
-0.14 11.02% 1M
-1.92 62.95% 6M
-24.12 95.52% YTD
-24.62 95.61% 1Y
-10,360.12 99.99% 3Y
-241,311.37 100.00% 5Y
-878,849,998.87 100.00% 10Y
-2,402,662,498.87 100.00% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.04 3.67%
ISIN
US47010C3007
Symbol
JAGX
Industry

Key metrics

Basic
Market capitalization
$4.2m
Enterprise Value
$31.5m
Net debt
$27.2m
Cash
$3.5m
Shares outstanding
3.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.4 | 0.3
EV/Sales
2.7 | 2.2
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
18.3%
Return on Equity
-394.0%
ROCE
-259.5%
ROIC
-
Debt/Equity
5.5
Financials (TTM | estimate)
Revenue
$11.8m | $14.3m
EBITDA
$-32.7m | $-23.7m
EBIT
$-34.6m | $-28.5m
Net Income
$-40.3m | $-89.6m
Free Cash Flow
$-26.3m
Growth (TTM | estimate)
Revenue
12.5% | 22.4%
EBITDA
-21.0% | 18.2%
EBIT
-19.5% | 7.5%
Net Income
-6.8% | -132.8%
Free Cash Flow
9.4%
Margin (TTM | estimate)
Gross
81.9%
EBITDA
-277.7% | -
EBIT
-294.0%
Net
-341.9% | -626.3%
Free Cash Flow
-223.1%
More
EPS
$-26.6
FCF per Share
$-7.1
Short interest
2.5%
Employees
49
Rev per Employee
$240.0k
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Jaguar Health, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Jaguar Health, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
12 12
13% 13%
100%
- Direct Costs 2.13 2.13
2% 2%
18%
9.65 9.65
15% 15%
82%
- Selling and Administrative Expenses 27 27
20% 20%
231%
- Research and Development Expense 15 15
2% 2%
129%
-33 -33
21% 21%
-278%
- Depreciation and Amortization 1.91 1.91
1% 1%
16%
EBIT (Operating Income) EBIT -35 -35
20% 20%
-294%
Net Profit -40 -40
7% 7%
-342%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Accesswire
10 days ago
SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited approval pathway SAN FRANCISCO, CA / ACCESS Newswire / December 15, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jag...
Neutral
Accesswire
15 days ago
Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected SAN FRANCISCO, CA / ACCESS Newswire / December 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Neutral
Accesswire
17 days ago
Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing ...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today